Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The burden caused by Alzheimer’s disease and other dementias represents one of the biggest problems for our healthcare systems. The last medicine was approved in 2002 and today we only have symptomatic treatments. ARUK-ODDI brings together chemists, biologist, psychiatrists and neuroscientists, many of them with pharmaceutical background, aiming to accelerate the discovery of novel and effective treatments.

Q: Why is Alzheimer's disease such an important medical problem?

John Davis: Alzheimer's disease and the other dementias that are caused by other neurodegenerative diseases represent one of the biggest problems we face in our healthcare system today. At the moment, there are about 800,000 people living with dementias in the country and that number is only growing. By about 2050 we expect that to top 2 million people. That is twice the population of Birmingham, or over twice the population of Oxfordshire; it is a huge problem. Unfortunately, this also affects women particularly badly. A lot of the care that is required to look after people with dementia falls on the shoulders of women. And you may not realise this but dementia is one of the leading causes of death for women over 65.

Q: Why is a there a need to improve treatments for Alzheimer's disease?

JD: The last medicine that was approved in the UK for treating patients with Alzheimer's disease was approved in 2002. That is an awful long time ago, and doctors don't have many tools in their tool box with which to treat patients, so we desperately need new treatments. The other problem is that the treatments that we have today are all what we called symptomatic treatments. They treat the underlying memory loss, they try and improve your memory. Unfortunately, they do not work for a particularly long time and they do not tackle at all the progression of the disease. Although they may give you some benefit for a period of time, once their effect wears off then you are back on the course of a steady decline. We really do need to identify drugs that tackle the pathogenesis of the disease.

Q: How is the Oxford Drug Discovery Institute helping to discover new treatments for Alzheimer's disease?

JD: The Oxford Drug Discovery Institute is one of three institutes that have been funded by the charity Alzheimer's Research UK. Our role is to try and bring forward the basic research that is developed within academic settings such as the Universities, and start to turn that work into drugs. Alzheimer's Research UK has a campaign called Defeat Dementia, and it aims to raise £100 million for research over 5 years. This a huge effort; it is all part of the Global Initiative, which the UK has played a leading role in, to tackle Alzheimer's disease head on and meet the challenge of producing new treatments by 2025 - or at least the germ of a new treatment by 2025.

Q: What are the most important lines of research that have developed over the last 5-10 years?

JD: It has been a particularly interesting and exciting time over the last decade for research into Alzheimer's and other neurodegenerative diseases. Over the next year or so we are going to see the pivotal trials for a number of anti-amyloid approaches, and that was the main thrust of many efforts over the last decade. Those results will be extremely exciting: they will tell us whether or not some of our basic hypothesis have been on the right track and we will be able to build on that.

Another very exciting area is the emergence of genetics. Because we can gather data now from large numbers of people we can look into the risk factors which might contribute towards a particular individual having Alzheimer's disease. Those studies have honed in on one particular mechanism: neuroinflammation. There is a lot of excitement amongst academic groups and amongst pharma to dig deep into those neuroinflammatory mechanisms, and that is one area we will be focusing on in our Institute.

Q: Why does your line of research matter and why should we fund it?

JD: Alzheimer's disease is a huge burden. It affects women a lot, it affects many many families; one in five families will have someone with dementia. We are all getting older, and there are less young people to look after us. It has been calculated that by 2017 or a few years after there won't even be enough people there to care for people with Alzheimer's disease. It is imperative that we find new drugs and find them fast. With the developing nations' populations living longer as well, globally there will be a huge number of people suffering from dementia. In the UK alone the costs of caring amount to about £24 billion; globally that is several hundred billion. That is equivalent to the GDP of small countries in the EU. It is a massive burden and we have to do something about it now.

Q: How does your research fit into translational medicine within the department?

JD: The Division of Medical Sciences has made translational research one of its main thrusts and our Department is all about translation. We are trying to develop these new areas of biology and bring them forward. The main job for us is to de-risk these new areas of biology, so that pharma, biotech and funders will pitch in to push the research onto the final delivery or a drug. That is our raison d'être, our whole purpose. In our Institute, we are chemists, biologists, many of us with pharma background. We know how to make drugs and we have been parachuted effectively into the academic system so that we can help achieve that translation.

John Davis

ARUK Oxford Drug Discovery Institute

Housed within the Target Discovery Institute, the Alzheimer's Research UK Oxford Drug Discovery Institute (ODDI) juxtaposes drug discovery expertise alongside scientific and academic understanding of patients, disease mechanisms and model systems.
Led by Dr John Davis, ODDI aims to translate cutting edge academic science into drug discovery, and to prosecute projects from target to lead status, and beyond.

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.